Panagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, Carolyn Krasner, Neil Horowitz, Susana Campos, Alexi A Wright, Joyce F Liu, Meghan Shea, Oladapo Yeku, Cesar Castro, Madeline Polak, Elizabeth K Lee, Hannah Sawyer, Brittany Bowes, John Moroney, Su-Chun Cheng, Nabihah Tayob, Sara Bouberhan, David Spriggs, Richard T Penson, Gini F Fleming, Marisa R Nucci, Ursula A Matulonis
Importance: Although the activity of pembrolizumab and lenvatinib (the only US Food and Drug Administration-approved immunotherapy for mismatch repair proficient endometrial cancer [MMRP EC]) is compelling, there are no biomarkers of response and most patients do not tolerate, do not respond to, or develop resistance to this regimen, highlighting the need for additional, potentially biomarker-driven therapeutic approaches for patients with recurrent MMRP EC. Objective: To assess the potential positive outcomes and safety of the combination of the polyadenosine diphosphate-ribose polymerase inhibitor talazoparib and the programmed cell death ligand 1 (PD-L1) inhibitor avelumab in recurrent MMRP EC...
July 28, 2022: JAMA Oncology